Constellation Pharmaceuticals (NASDAQ:CNST) had its target price hoisted by analysts at Oppenheimer from $14.00 to $18.00 in a research note issued to investors on Tuesday, April 2nd, Stock Target Advisor reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target suggests a potential upside of 46.70% from the company’s previous close. Oppenheimer also issued estimates for Constellation Pharmaceuticals’ FY2023 earnings at ($5.14) EPS.
CNST has been the topic of several other research reports. Robert W. Baird assumed coverage on Constellation Pharmaceuticals in a research report on Monday, January 28th. They issued an “outperform” rating and a $17.00 price target on the stock. Zacks Investment Research raised Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a report on Wednesday, January 9th. HC Wainwright assumed coverage on Constellation Pharmaceuticals in a report on Thursday, December 20th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, ValuEngine lowered Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $16.82.
Shares of CNST traded down $0.17 during midday trading on Tuesday, reaching $12.27. 19,000 shares of the stock were exchanged, compared to its average volume of 81,768. The stock has a market capitalization of $318.45 million and a P/E ratio of -2.43. Constellation Pharmaceuticals has a twelve month low of $4.01 and a twelve month high of $14.04.
Several large investors have recently made changes to their positions in the company. Svennilson Peter purchased a new stake in Constellation Pharmaceuticals in the 4th quarter valued at approximately $18,759,000. Vanguard Group Inc. acquired a new position in Constellation Pharmaceuticals in the 3rd quarter valued at $989,000. EcoR1 Capital LLC acquired a new position in Constellation Pharmaceuticals in the 3rd quarter valued at $1,884,000. VHCP Management II LLC acquired a new position in Constellation Pharmaceuticals in the 3rd quarter valued at $4,891,000. Finally, Vanguard Group Inc acquired a new position in Constellation Pharmaceuticals in the 3rd quarter valued at $989,000. 60.01% of the stock is currently owned by institutional investors and hedge funds.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Recommended Story: How can you know how many shares are floating?
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.